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Abstract
Enterococcus faecium has become a nosocomial pathogen of major importance, causing infections that are difficult to treat
owing to its multi-drug resistance. In particular, resistance to the b-lactam antibiotic ampicillin has become ubiquitous
among clinical isolates. Mutations in the low-affinity penicillin binding protein PBP5 have previously been shown to be
important for ampicillin resistance in E. faecium, but the existence of additional resistance determinants has been
suggested. Here, we constructed a high-density transposon mutant library in E. faecium and developed a transposon
mutant tracking approach termed Microarray-based Transposon Mapping (M-TraM), leading to the identification of a
compendium of E. faecium genes that contribute to ampicillin resistance. These genes are part of the core genome of E.
faecium, indicating a high potential for E. faecium to evolve towards b-lactam resistance. To validate the M-TraM results, we
adapted a Cre-lox recombination system to construct targeted, markerless mutants in E. faecium. We confirmed the role of
four genes in ampicillin resistance by the generation of targeted mutants and further characterized these mutants regarding
their resistance to lysozyme. The results revealed that ddcP, a gene predicted to encode a low-molecular-weight penicillin
binding protein with D-alanyl-D-alanine carboxypeptidase activity, was essential for high-level ampicillin resistance.
Furthermore, deletion of ddcP sensitized E. faecium to lysozyme and abolished membrane-associated D,D-carboxypeptidase
activity. This study has led to the development of a broadly applicable platform for functional genomic-based studies in E.
faecium, and it provides a new perspective on the genetic basis of ampicillin resistance in this organism.
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Introduction
Enterococci rank third overall as causative agents of healthcare-
associated infections [1,2]. Up to the late 1980s, Enterococcus faecalis
was responsible for practically all enterococcal infections, but
starting from the 1990s nosocomial infections with E. faecium
became more frequent. Currently E. faecium causes approximately
40% of all enterococcal infections that are acquired during
hospital stay [2–4]. Clinical isolates of E. faecium have rapidly
accumulated antibiotic resistance genes, including those for
clinically important antibiotics such as ampicillin and vancomycin,
which leads to treatment failure and increased mortality rates
[2,5–7]. In the USA, nosocomial infections caused by ampicillin-
resistant E. faecium (ARE) were first detected in the 1980s and the
resistance rates were steadily increasing up to 80% of E. faecium
isolates in the 1990s [8,9]. Vancomycin-resistant E. faecium (VRE)
also emerged in the late 1980s and increased rapidly during the
1990s [9,10]. Currently, VRE is widespread among clinical E.
faecium strains in North America, but less common in hospital-
acquired infections in Europe [11]. Ampicillin resistance has
spread much further and it is currently being reported in over 80%
of clinical E. faecium isolates from all over the world [1,2]
(European Antimicrobial Resistance Surveillance Network:
http://www.ecdc.europa.eu/en/activities/surveillance/EARS-
Net/Pages/index.aspx). In addition to ARE and VRE, the
emergence of E. faecium strains that are resistant to new classes
of antibiotics is challenging the few remaining therapeutic options
[12–14]. Thus, the development of new anti-enterococcal agents
may become critical for the successful treatment of infections
caused by this multi-drug resistant organism in the future.
The intrinsic resistance to b-lactam antibiotics of enterococci
was reported 60 years ago, soon after the introduction of penicillin
in the early 1940s, when enterococci were found to be
considerably less susceptible to b-lactams than streptococci [15].
Mutations in the high-molecular weight class B penicillin-
binding protein 5 (PBP5) have been considered the main cause
for the resistance to b-lactams in E. faecium. Upregulated
expression of pbp5 and/or mutations in the 39 end of the gene
lead to a further reduced susceptibility to ampicillin [16–18].
However, several studies have suggested that the high minimum
inhibitory concentration (MIC) of ampicillin against E. faecium is
not exclusively due to the presence of low-affinity PBP5 but also to
other genes or mechanisms that remain to be identified [19,20].
Recently, Mainardi et al. [21,22] showed in a spontaneous mutant
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containing ampicillin, that the D,D-transpeptidase activity of the
PBPs could be bypassed by a b-lactam resistant L,D-transpepti-
dase (Ldtfm) that catalyses the formation of 3R3 cross-links
between peptidoglycan side chains instead of the classical 4R3
cross-links. A D,D-carboxypeptidase, termed DdcY, is an impor-
tant component in the L,D-transpeptidase mediated pathway of
peptidoglycan cross-linking. However, the ddcY gene is only
present in a small proportion of E. faecium isolates [23], again
suggesting that additional ampicillin resistance determinants in E.
faecium remained to be identified and characterized.
Genome-wide studies of clinical E. faecium isolates have long
been hampered by a lack of appropriate genetic tools. In this
study, we describe the construction of a high density mariner
transposon mutant library and the development of a powerful tool
for functional genomics, termed Microarray-based Transposon
Mapping (M-TraM), in E. faecium. By comparing the mutant
library following growth in the presence or absence of ampicillin,
we identified a compendium of genes affecting the sensitivity to
ampicillin. Targeted mutants of the identified genes with predicted
roles in cell wall synthesis were generated for further character-
ization, which resulted in the identification of several intrinsic
ampicillin resistance determinants in E. faecium. These ampicillin
resistance determinants may serve as targets for the development
of novel antimicrobial therapeutics.
Results
Construction of a high-density transposon mutant library
in E. faecium
To attempt genome-wide transposon mutagenesis of the E.
faecium genome, we constructed the transposon delivery plasmid
pZXL5. As shown in Figure S1, this plasmid was composed of a
Gram-positive thermo-sensitive replicon, a gentamicin resistant
mariner transposon with two outward-facing T7 promoters, a nisin-
inducible mariner transposase, a ColE1 replicon and a cat gene. The
sequence of pZXL5 was determined by Sanger-sequencing of both
DNA strands (Baseclear; Leiden, The Netherlands) and was
deposited in GenBank (GenBank Accession Number: JQ088279).
Using pZXL5, we have produced a transposon mutant library
in E. faecium strain E1162, an ampicillin-resistant clinical isolate
from a bloodstream infection, for which a draft genome sequence
has previously been determined [24]. The randomness of the
transposon insertions and the absence of multiple transposon
insertion events were determined by randomly selecting 17
mutants from the library and carrying out Southern blot
hybridizations, using a fragment of the transposon as a probe
(Figure S2A), as well as inverse PCR and sequence analysis to
determine the location of the transposon insertion point (Figure
S2B). The results showed that each mutant carries a single
transposon inserted in the genome, and that the transposon was
distributed in different loci in the 17 mutants. PCR footprinting
was performed to estimate the genome-wide coverage of
transposon insertions in the mutant library (Figure 1). An
outward-facing primer was designed based on the mariner
transposon sequence. The other PCR primer was designed for
three target genes, ddl (which encodes a D-alanine:D-alanine ligase
that is essential for bacterial cell wall biosynthesis [25]), esp (which
is non-essential and encodes a large surface protein involved in
biofilm formation and infection [26–28]) and nox (which is a non-
essential gene encoding a predicted NADH oxidase). Genomic
DNA isolated from the pooled mutant library was used as a
template. A range of products can be amplified by these primers,
each corresponding to a transposon insertion mutant in the
library. If a gene is essential for survival, its transposon insertion
mutants should not be present in the library after overnight
growth, and consequently no PCR products should be amplified in
the corresponding size range. As expected, no PCR product was
detected within the ddl gene (Figure 1) while many PCR bands
were found in esp and nox at intervals of less than 100 bp,
indicating the transposon insertions covered the nonessential genes
of the genome at high density. Furthermore, mapping the
transposon insertion sites to the complete genome sequence of E.
faecium Aus0004 [29] revealed that transposon insertions were
randomly distributed over the genome of this strain and not
confined to a specific chromosomal region (data not shown). To
establish whether pZXL5 has broad applicability in E. faecium we
attempted to transform four other clinical E. faecium isolates from
different geographic origins (Table S1) with pZXL5 using our
optimized electroporation protocol. All four strains were efficiently
transformed with transformation efficiencies ranging between 110
and 10
5 transformants per mg DNA (Figure S2C). We then
continued to generate transposon mutant libraries in two of these
strains (Figure S2D). These observations show that the transposon
mutagenesis approach that we initially developed for strain E1162,
can also be used for functional genomics in other clinical E. faecium
isolates.
M-TraM is highly reproducible
As described in the Materials and Methods and in Figure 2, we
developed a technique to track the presence of all mutants in the
library by simultaneously mapping the transposon insertion sites
using microarray hybridization. We termed this technique M-
TraM for Microarray-based Transposon Mapping. To validate
the reproducibility of M-TraM, we independently grew two
aliquots containing approximately 10
7 cells from the library in
20 ml of BHI broth. After 20 hours of culturing at 37uC, genomic
Author Summary
Enterococcus faecium has emerged as an important
nosocomial pathogen around the world. Clinical E. faecium
isolates are often resistant to multiple antibiotics, thereby
complicating therapeutic interventions. However, the
molecular mechanisms that contribute to the recent
emergence of E. faecium as a nosocomial pathogen of
major importance are only poorly understood, which is, at
least partially, due to the lack of appropriate genetic tools
for the study of this organism. Here, we developed a
systematic genome-wide strategy, based on transposon
mutagenesis and microarray-based screening, to identify E.
faecium genes that contribute to ampicillin resistance. We
also adapted the Cre-lox recombination system to
construct targeted, markerless mutants in E. faecium.
These tools enabled us to perform both high-throughput
genome-wide analysis and specific targeted investigations
in a clinical E. faecium isolate. We comprehensively
identified, confirmed, and characterized a compendium
of genes affecting the sensitivity to ampicillin in E. faecium.
The identified intrinsic ampicillin resistance determinants
are highly conserved among E. faecium, indicating that this
organism has a high potential to evolve towards ampicillin
resistance. These ampicillin-resistance determinants may
serve as targets for the development of novel antimicro-
bial therapeutics.
Ampicillin Resistance in E. faecium
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generation of cDNA. The cDNA samples were labeled with Cy3
and Cy5 respectively and hybridized to a microarray that was
designed using the E. faecium E1162 genome sequence. The result
showed that M-TraM is highly reproducible, with a correlation
coefficient of 0.94 between the two independent experiments
(Figure 2C).
Identification of E. faecium genes involved in ampicillin
resistance by M-TraM
To identify genes required for ampicillin resistance, we grew the
pool of mutants in the presence or absence of a subinhibitory
concentration (20 mgm l
21) of ampicillin, and used M-TraM to
determine which mutants were selectively lost during culturing in
the presence of ampicillin. Eleven genes belonging to a variety of
functional categories were identified to be involved in ampicillin
resistance (Table 1). Four genes involved in cell wall biogenesis
were identified and we decided to further focus on these genes.
The EfmE1162_0447 (ddcP) and EfmE1162_1886 (ldtfm) genes
were predicted to encode a D-alanyl-D-alanine carboxypeptidase
(D,D-carboxypeptidase, DdcP) and beta-lactam-insensitive pepti-
doglycan transpeptidase (L,D-transpeptidase, Ldtfm), respectively.
Previous studies have shown that a different D,D-carboxypepti-
dase (DdcY) and Ldtfm were able to bypass the D,D-transpeptidase
activity of the PBPs by forming 3R3 cross-links instead of the
classical 4R3 cross-links thereby conferring resistance to b-lactams
[21,23]. DdcP and DdcY only share 13.7% amino acid identity
and have a completely different protein domain architecture as
DdcY is a b-lactam-insensitive VanY-type carboxypeptidase
[23,30], while DdcP belongs to the family of low-molecular-
weight (LMW) PBPs [30] (Figure S3). The ddcY gene is absent from
24 (including E1162) of the 29 E. faecium genomes available (on 9
January 2012) at NCBI Genomes. The ddcP gene is conserved in
all 29 E. faecium genomes. EfmE1162_0975 (pgt) was predicted to
encode a glycosyl transferase group 2 family protein which is 63%
identical to GltB, a protein that was proposed to be involved in
glycosylation of cell wall teichoic acid in serotype 4b Listeria
monocytogenes [31]. EfmE1162_2487 (lytG) was predicted to encode
an exo-glucosaminidase that could be acting as a peptidoglycan
hydrolase involved in cell wall lysis, remodeling and cell division
[32]. An overview of the protein domain architecture and
predicted cellular localization of DdcP, Ldtfm, Pgt and LytG is
provided in Figure S3. Like the ddcP gene, the ldtfm, pgt and lytG
genes are present in all the 29 E. faecium genomes as well,
suggesting these genes are part of the E. faecium core genome.
Notably the E. faecium ampicillin resistance determinants ddcP, ldtfm
and pgt do not have homologs (defined here by proteins with
.30% amino acid identity) in E. faecalis. It should be noted that
the L,D-transpeptidase from E. faecalis that was biochemically
characterized by Magnet et al., [33] has not been experimentally
linked to b-lactam resistance in E. faecalis and is only remotely
related (26% amino acid identity) to ldtfm.
Comparison of ampicillin sensitivities of targeted
mutants and wild-type E1162
To validate the results of the M-TraM screen and to further
characterize the role of the identified genes in ampicillin
resistance, we constructed targeted mutants in the ddcP, ldtfm and
pgt genes, which were identified with the most significant P-values
(Table 1) and have predicted functions in cell wall biogenesis. We
Figure 1. Footprinting analysis of the transposon mutant library. (A) Schematic overview of the transposon footprinting strategy. PCR is
performed using a gene specific primer and a primer corresponding to the transposon sequence. (B) Agarose gel electrophoresis of transposon
footprinting on the essential gene ddl (lane 1), and the non-essential genes nox and esp (lane 2 and 3, respectively). Each band represents a PCR
product of a different size, corresponding to a transposon insertion in a different position. The red box represents the product size range expected for
transposon insertions within the essential ddl gene.
doi:10.1371/journal.pgen.1002804.g001
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inactivation could confer hyper-resistance to ampicillin, as
suggested by the M-TraM data. Targeted deletion mutants of
ddcP, pgt, and lytG were generated using a novel Cre-lox-based
system for the generation of markerless mutants in E. faecium that
we developed as part of this study (Figure S4). For ldtfm no double
cross-over mutant could be constructed and instead a single cross-
over mutant was constructed using the pWS3 vector [34]. Mutants
of ddcP, ldtfm, and lytG were also complemented in trans and the
ampicillin resistance of E1162 (wild-type), the mutants and the
complemented strains was determined. The pgt mutant could not
be complemented as constructs containing the pgt gene could not
be transformed to either Escherichia coli or E. faecium, presumably
due to toxicity of the gene product. In the absence of ampicillin we
did not detect significant differences in growth speed or cell density
upon entry into stationary phase between wild-type and the
Figure 2. Schematic diagram and reproducibility of M-TraM. (A) Schematic overview of the M-TraM screening. In yellow: inverted terminal
repeats (ITRs) of the himar1 transposon with outward-facing T7 promoters; in blue: the gentamicin resistance gene in the transposon. Genomic DNA
is isolated from the E. faecium mutant library. DNA is digested with the restriction enzyme AluI, and the DNA fragments are circularized by self-
ligation. The transposon-chromosome junction together with an ITR and a T7 promoter is amplified by PCR with primers (blue arrow) that hybridize
to the transposon. To eliminate foreign DNA fragments that ligated into the circularized DNA of transposon-chromosome junctions, the PCR products
were re-digested with AluI. The purified DNA fragments are used as template in the in vitro transcription reaction. The resulting RNA products are
reverse transcribed into cDNA. After labelling, the cDNA is used for microarray hybridization. (B) Schematic overview of the screening strategy to
identify conditionally essential genes by M-TraM. A chromosomal region encompassing three genes (A, B, and C) from three different mutants (1, 2,
and 3) is shown. Each mutant carries a single transposon insertion (blue) that disrupts the function of the gene. Mutant libraries are grown in a
control condition (e.g., BHI) and a test condition (e.g., in the presence of ampicillin). All the three genes are non-essential for growth in the control
condition. Gene B is required only for the test condition, so mutant 2 exhibits attenuated growth or poorer survival only in the test condition, and will
consequently be reduced or be entirely lost from this library (indicated by light shading). M-TraM samples are generated from the two conditions,
labelled with different dyes, and hybridized to a microarray. The DNA probes of gene A and gene C on the microarray will hybridize to the samples
generated from both conditions. However, the cDNA sample of gene B will be present at reduced levels only in the test condition. By comparing the
signal intensity from the two conditions for each probe, genes involved in growth or survival of the test condition can be identified. (C)
Reproducibility of M-TraM. Log-log plot of the microarray signal intensities from two independent experiments of mutant libraries grown under non-
selective conditions in BHI broth.
doi:10.1371/journal.pgen.1002804.g002
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with 20 mgm l
21 ampicillin, the DddcP mutant was dramatically
affected in its growth (Figure 3A). Growth of the ldtfm::pWS3 and
Dpgt mutants was also poorer than wild-type (Figure 3B and 3C).
The in trans complemented strains of the DddcP and ldtfm::pWS3
strains could fully or partially restore the ampicillin resistance to
wild-type levels (Figure 3A–3C). The DlytG mutant had a growth
rate that was similar to the parental strain’s (0.99860.007 h
21 for
DlytG vs. 0.98960.018 h
21 for E1162) but could grow to slightly
higher optical densities (Figure 3D). The in trans complemented
lytG mutant exhibited a significantly lower growth rate
(0.85960.017 h
21) in exponential phase (Figure 3D). The empty
vector had no effect on the growth of the mutants in BHI
supplemented with 20 mgm l
21 ampicillin (data not shown). MICs
of ampicillin against the wild-type E1162 and DddcP, ldtfm::pWS3,
Dpgt and DlytG strains were determined by microdilution in cation-
adjusted Muller-Hinton broth as 43, 8, 16, 27 and 43 mgm l
21,
respectively, which is in accordance with the growth performance
of the mutants in BHI with 20 mgm l
21 ampicillin (Figure 3). The
seemingly contradictory observation that the ldtfm::pWS3 mutant
can grow in BHI medium supplemented with ampicillin at a
concentration above the MIC can be explained by the differences
in growth media used and the approximately 4-fold larger
inoculum size used in the growth experiments in BHI compared
to the inoculum size used in the MIC determinations. The MIC of
vancomycin was determined to be 0.5 mgm l
21 for all strains.
Comparative analysis of the transcriptome of E. faecium
E1162 during exponential growth in the absence and
presence of ampicillin
We used microarray-based transcriptome analysis on exponen-
tially growing (OD660=0.3) E. faecium E1162 cultures in BHI
medium with or without 20 mgm l
21 ampicillin to identify genes
that are regulated by the exposure to sub-MIC levels of ampicillin.
Compared to the untreated control, only sixteen genes were
identified to be differentially regulated between the two conditions
and none of these genes were upregulated more than 2.1-fold in
the presence of ampicillin (Table S2), indicating that E. faecium
does not require major transcriptional rearrangements to cope
with the presence of sub-inhibitory levels of ampicillin. None of the
genes that were identified by M-TraM were identified to be
differentially regulated by the presence of ampicillin, which
indicates that the identified ampicillin resistance determinants
are constitutively expressed, even in the absence of ampicillin.
Mutations in ddcP and ldtfm increase sensitivity to
lysozyme
After the identification of ddcP, ldtfm and pgt as ampicillin
resistance determinants, we studied the susceptibility of the wild-
type strain E1162 and its mutants to another compound targeting
the cell wall, i.e. lysozyme, which is one of the most important
antimicrobial enzymes of the host innate immune system.
Lysozyme kills Gram-positive bacteria by enzymatic lysis of the
bacterial cell wall [35]. The results demonstrated that deletion of
pgt had no significant effect on lysozyme resistance, while DddcP
and ldtfm::pWS3 mutants were significantly more sensitive to
lysozyme challenge than the wild-type strain (Figure 4). The in trans
complemented strains of DddcP and ldtfm::pWS3 could restore the
resistance to lysozyme. Hence, ddcP and ldtfm contribute not only
to b-lactam resistance but also to the resistance against the
peptidoglycan-hydrolyzing enzyme lysozyme.
Disruption of ddcP abolishes membrane-associated D,D-
carboxypeptidase activity of E. faecium E1162
Of all novel ampicillin resistance determinants identified in this
study, the ddcP gene contributes most to ampicillin resistance in E.
faecium E1162. The DdcP protein was annotated as a D-alanyl-D-
alanine carboxypeptidase but a functional study confirming this
Table 1. E. faecium genes involved in ampicillin resistance as determined by M-TraM analysis.
LocusTag




EfmE1162_0447 ZP_06676292 ddcP D-alanyl-D-alanine carboxypeptidase 32.5 4.4610
27
EfmE1162_2490 ZP_06678189 oxidoreductase, Gfo/Idh/MocA family 11.8 8.6610
24
EfmE1162_1886 ZP_06677646 ldtfm beta-lactam-insensitive peptidoglycan transpeptidase11.1 3.0610
25
EfmE1162_0975 ZP_06676820 pgt glycosyl transferase, group 2 family protein 10.6 4.8610
25
EfmE1162_0256 ZP_06676101 metallo-beta-lactamase superfamily protein 10.0 4.8610
24
EfmE1162_2260 ZP_06678020 dihydrodipicolinate synthase 7.3 3.0610
24
EfmE1162_2058 ZP_06677818 hydrolase, alpha/beta hydrolase fold family 7.1 1.7610
24
EfmE1162_0669 ZP_06676514 nitroreductase family protein 6.8 2.8610
24
EfmE1162_1943 ZP_06677703 chromosomal replication initiator protein DnaA 5.5 7.6610
24
EfmE1162_0064 ZP_06675909 ribosomal protein L33 5.2 2.8610
24
EfmE1162_2487 ZP_06678186 lytG Exo-glucosaminidase 27.5 6.3610
24
aIndicates the gene containing the transposon insertion.
bIndicates the fold-change derived from the ratio of the unselected control library to the ampicillin competitively selected library. e.g. the value 32.5 means that the
relative quantity of mutants of EfmE1162_0447 in the ampicillin-selected library was 32.5-fold less than in the control library grown without selective pressure. This
indicates that mutants in EfmE1162_0447 have a lower relative fitness in the presence of ampicillin than wild type cells. The value of 27.5 for EfmE1162_2487 indicates
that mutants in this gene outgrow the other mutants in the ampicillin-selected library by 7.5-fold, indicating that mutants of EfmE1162_2487 have higher relative fitness
in the presence of ampicillin.
doi:10.1371/journal.pgen.1002804.t001
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PLoS Genetics | www.plosgenetics.org 5 June 2012 | Volume 8 | Issue 6 | e1002804Figure 3. The effect of targeted mutations of ddcP, ldtfm, pgt, and lytG on growth of E. faecium in the presence of ampicillin. Overnight
cultures of mutants and wild-type E. faecium were inoculated at an initial cell density of OD660 0.0025 in BHI with 20 mgm l
21 ampicillin. Growth
curves of strain E1162, the different mutants (panel A: DddcP; panel B: ldtfm::pWS3; panel C: Dpgt; panel D: DlytG) and in trans complemented strains
are shown. Growth curves are mean data of three independent experiments.
doi:10.1371/journal.pgen.1002804.g003
Figure 4. Percentage survival of E. faecium cells following a lysozyme challenge. Survival of the indicated wild-type, mutant strains and in
trans complemented strains following a 30-minute incubation in PBS containing 0.5 mg ml
21 lysozyme relative to the survival of the strains after a
30-minute incubation in PBS without lysozyme. Bars represent the standard deviation of the mean of three independent experiments. Asterisks
represent significant differences (P,0.005 as determined by a two-tailed Student’s t-test) between the indicated mutants and the wild-type strain.
doi:10.1371/journal.pgen.1002804.g004
Ampicillin Resistance in E. faecium
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function, we determined the D-alanyl-D-alanine carboxypepti-
dase activity in cellular extracts of E1162, the DddcP mutant and
the in trans complemented strain DddcP+ddcP.A ss h o w ni n
Figure 5, the D-alanyl-D-alanine-carboxypeptidase activity of
DddcP membrane extracts was completely abolished. In the
complemented DddcP+ddcP strain enzymatic activity was restored
in the membrane fraction, revealing that DdcP is responsible for
D-alanyl-D-alanine carboxypeptidase activity in E. faecium
E1162. The D,D-carboxypeptidase activity was approximately
5 fold lower in the cytoplasmic fractions than in the membrane
fractions (data not shown), strongly suggesting that the DdcP
protein is associated with the membrane. When E. faecium E1162
was grown in the presence of 20 mgm l
21 ampicillin, all D-
alanyl-D-alanine carboxypeptidase activity was undetectable,
which is in accordance with the designation of DdcP as a LMW-
PBP.
Confirmation of pbp5 as an important ampicillin
resistance determinant in E. faecium E1162
Notably, pbp5 was not identified in this M-TraM screen even
though this gene has been implicated in high-level ampicillin
resistance in E. faecium [16–18]. Our failure to identify pbp5 by
M-TraM may partially be explained by the presence of an AluI
restriction site on one of the two microarray probes for pbp5.
The other microarray probe maps to an internal region of the
pbp5 gene and is located on a small AluI restriction fragment
with a window of 158 nucleotides for the transposon insertion.
Previous genome-wide studies using transposon mutagenesis
have shown that transposon insertions might fail to fully
inactivate the target genes. The failure is commonly found with
insertions situated near either end of a gene, but has also been
observed with internal insertions [36,37], after which genes
might be capable of intracistronic complementation. We
constructed targeted insertional mutants of pbp5, ddcP and ldtfm
by the insertion of the plasmid pWS3 59 t ot h eg e n ep r o b e sa n d
close to the central region of the gene. Consistent with the M-
TraM results and the phenotypes of the markerless mutants, the
insertional mutants of ddcP (data not shown) and ldtfm (Figure 3B)
were sensitized to ampicillin. Surprisingly the insertional
mutation in pbp5 did not significantly affect the sensitivity to
ampicillin (Figure 6), implying that insertional mutation (by
either a plasmid or a transposon) could not fully disrupt pbp5.
Therefore a markerless deletion mutant for pbp5 was generated
to completely abolish the function of this gene using the Cre-lox
system described above. To our knowledge, a targeted mutant of
the pbp5 gene has not been generated previously in E. faecium.
The pbp5 mutant was unable to grow in cultures containing
20 mgm l
21 ampicillin and the ampicillin resistant phenotype
could be partially be restored by in trans complementation of
Dpbp5 with the pbp5 g e n e( F i g u r e6 ) .T h eM I Co fa m p i c i l l i nf o r
Dpbp5 was determined by broth microdilution to be only
0.2 mg/ml. Our results revealed that the relative contribution of
pbp5, ddcP, ldtfm and pgt to ampicillin resistance in E. faecium
E1162 can be summarized as pbp5&ddcp.ldtfm.pgt.T h epbp5
m u t a n tw a sa l s oa s s a y e df o ri t ss u r v i v a li nt h ep r e s e n c eo f
lysozyme, but no significant difference was found with the
parental strain E1162( d a t an o ts h o w n ) .
Discussion
Ampicillin resistance in E. faecium has emerged in the late 1970s
and has spread rapidly since [38]. Practically all clinical isolates
are currently resistant to ampicillin. The resistance to b-lactams of
E. faecium complicates the treatment of infections with this
organism, particularly when resistance to other antibiotics has
also been acquired. The goal of the research described here was to
identify genes involved in ampicillin resistance in E. faecium in a
high-throughput fashion. We developed a system for the
generation of a large random transposon mutant library in E.
faecium, coupled to a microarray-based screening approach (termed
M-TraM) to simultaneously monitor the relative fitness of
individual mutants undergoing selection by growth in the presence
of ampicillin.
The lack of appropriate genetic tools has long been a bottleneck
for the studies of E. faecium. In this study, we constructed a random
high-density transposon mutant library in E. faecium, developed a
Figure 5. D,D-carboxypeptidase activity in E. faecium mem-
brane fractions. Membrane extracts were isolated from the indicated
strains grown in BHI medium (with or without the addition 20 mgm l
21
ampicillin) until an OD600 of 0.7. The D,D-carboxypeptidase activity
(nmol min
21 mg
21) was defined as the number of nmoles of D-Ala
released from pentapeptide (7.5 mM) per min and per mg of protein in
the membrane fractions. D-Ala was assayed using D-amino acid oxidase
coupled to peroxidase. Bars represent the standard deviation of the
mean of three independent experiments. Asterisks represent significant
difference (
*P,0.05,
**P,0.005 as determined by a two-tailed Student’s
t-test) between the different strains and conditions.
doi:10.1371/journal.pgen.1002804.g005
Figure 6. Growth curves of E. faecium E1162 and pbp5 mutants
in BHI with 20 mgm l
21 ampicillin. Overnight cultures of wild-type
E. faecium E1162, the insertional pbp5 mutant (pbp5::pWS3), the
markerless deletion mutant Dpbp5 and the in trans complemented
deletion mutant (Dpbp5+pbp5) were inoculated at an initial cell density
of OD660 0.0025 in BHI with 20 mgm l
21 ampicillin. Growth curves are
mean data of three independent experiments.
doi:10.1371/journal.pgen.1002804.g006
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adapted the Cre-lox [39] recombination system to construct
targeted, markerless mutants in E. faecium, which enabled us to
perform high-throughput genome-wide analysis and specific
targeted investigations in a clinical E. faecium isolate.
When E. faecium is exposed to ampicillin the D,D-transpeptidase
activity of PBPs is inhibited, with the exception of the low-affinity
PBP5, which can catalyze the last cross-linking step of the D,D-
transpeptidation pathway of cell wall assembly [17]. This implies
that any D,D-transpeptidase activity conferred by genes other than
pbp5, is not essential for ampicillin resistance. Consequently, no
genes encoding D,D-transpeptidases were identified in this study.
However, in our transposon mutant screen, we identified a novel
D-alanyl-D-alanine carboxypeptidase (DdcP) that plays an impor-
tant role in resistance to ampicillin. DdcP is the only gene that is
responsible for D-alanyl-D-alanine carboxypeptidase activity
during exponential growth of strain E1162. The observation that
the enzymatic activity of DdcP is abolished in the presence of
ampicillin is in accordance with the prediction that DdcP is a
LMW-PBP. The in vivo functional roles of LMW-PBPs are
relatively poorly understood but they are generally not essential
for survival and are thought to contribute to peptidoglycan-
remodelling in both Gram-positive and Gram-negative bacteria
[40]. Deletion of the gene encoding a LMW-PBP can lead to an
increased sensitivity towards b-lactam antibiotics [41–42]. Al-
though a mechanistic understanding for this sensitive phenotype is
currently lacking, it has been proposed that these LMW-PBPs may
enzymatically inactivate b-lactams or, alternatively, save other
PBPs from inactivation by sequestration of the b-lactams to the
LMW-PBPs [41]. Further functional characterization of DdcP in
E. faecium, also involving strains that have higher and lower
resistance towards ampicillin than strain E1162, is needed to
identify the exact mechanism by which DdcP contributes to
ampicillin resistance in E. faecium. Previous biochemical studies
have indicated that Ldtfm is a crucial component of the b-lactam-
insensitive L,D-transpeptidation pathway, which catalyzes the
cross-links of tetrapeptides [21–23]. However, genetic evidence for
the role of Ldtfm in ampicillin resistance was so far lacking. Here,
we have constructed a mutant, confirming the role of this pathway
in ampicillin resistance in E. faecium. The identification of pgt as an
ampicillin resistance determinant in E. faecium suggests that wall
teichoic acid is involved in b-lactam resistance which is in line with
a similar observation in methicillin-resistant Staphylococcus aureus
(MRSA) strains [43]. None of the mutations had an effect on
vancomycin resistance of E. faecium, presumably because tetra-
peptide precursors for peptidoglycan crosslinks are present at levels
that are too low to confer resistance to this antibiotic in wild-type
and the mutant strains.
We did not generate mutants or performed functional analyses
to confirm the function of the other genes that were identified in
our M-TraM screening (Table 1). However, it seems likely that at
least some of these genes also contribute to ampicillin resistance in
E. faecium, in particular EfmE1162_2490 (predicted to function as
an NAD- or NADP-dependent oxidoreductase) and
EfmE1162_0256 (possibly acting as a zinc-dependent b-lacta-
mase), because the transposon mutants in these genes appear to
have a similar loss in fitness in the presence of ampicillin as the
transposon mutants in ldtfm and pgt (Table 1). The lytG gene was
the only gene that was identified in our screen which, upon
inactivation by a transposon, appeared to result in a hyper-
resistant phenotype. However, this phenotype could not be
confirmed in a markerless deletion mutant of lytG, which had
the same MIC for ampicillin as the wild-type strain. The observed
slightly higher optical density reached by DlytG as compared to
wild-type and the slower growth rate of the in trans complemented
lytG mutant may suggest that there is a subtle role for lytG in
ampicillin resistance in E. faecium but further experiments would be
required to exactly determine its role.
The recent emergence of E. faecium as a major nosocomial
pathogen can be explained by the acquisition of genes that
contribute to colonization or infection [26,44] and by the
acquisition of resistance to antibiotics, particularly to ampicillin
and vancomycin. Interestingly, resistance against ampicillin and
vancomycin emerged predominantly in E. faecium while both
resistances are virtually absent in E. faecalis [8]. This study provides
insights into the genetic basis of intrinsic b-lactam resistance in E.
faecium and identified the ampicillin resistance determinants DdcP,
Ldtfm and Pgt in this organism. All three genes are conserved in E.
faecium but absent from E. faecalis, indicating that E. faecium
possesses more innate b-lactam resistance determinants than E.
faecalis. This observation supports the concept that E. faecium has a
higher potential to develop high-level b-lactam resistance than E.
faecalis, thereby explaining the faster emergence of ampicillin
resistance in E. faecium than in E. faecalis [1,2,45].
We have identified several novel mechanisms, besides the low-
affinity penicillin-binding protein PBP5, that contribute to
ampicillin resistance in E. faecium. These proteins could serve as
targets for the development of novel therapeutics against this
multi-resistant organism. Our study showed that DdcP and Ldtfm
also contribute to resistance to lysozyme of E. faecium. An inhibitor
of these proteins may thus provide the dual benefit of compro-
mising resistance to the innate immune system as well as
enhancing antibiotic susceptibility. In the course of this study we
have also developed a number of novel genetic tools for E. faecium
allowing for genome-wide analysis of this bacterium. Further
functional genomic-based studies to understand the mechanisms
involved in colonization, infection and antibiotic resistance of this
important nosocomial pathogen are now a realistic opportunity for
future research.
Materials and Methods
Bacterial strains, plasmids, and growth conditions
E. faecium and E. coli strains used in this study are listed in Table
S1. The ampicillin-resistant E. faecium strain E1162 was used
throughout this study. This strain was isolated from a bloodstream
infection in France in 1996 and its genome has recently been
sequenced [24]. Unless otherwise mentioned, E. faecium was grown
in brain heart infusion broth (BHI; Oxoid) at 37uC. The E. coli
strains DH5a (Invitrogen) and EC1000 [46] were grown in Luria-
Bertani (LB) medium. Where necessary, antibiotics were used at
the following concentrations: chloramphenicol 4 mgm l
21 for E.
faecium and 10 mgm l
21 for E. coli, gentamicin 300 mgm l
21 for E.
faecium and 25 mgm l
21 for E. coli, spectinomycin 300 mgm l
21 for
E. faecium and 100 mgm l
21 for E. coli, and erythromycin
50 mgm l
21 for E. faecium (with added lincomycin at 50 mgm l
21)
and 150 mgm l
21 for E. coli. All antibiotics were obtained from
Sigma-Aldrich (Saint Louis, MO). Growth was determined by
measuring the optical density at 660 nm (OD660).
Construction of an E. faecium in vivo transposon
mutagenesis system
The transposon delivery plasmid, pZXL5, was constructed in
several steps. The Gram-positive lacZ gene of pCJK72 [47] was
PCR (Accuprime DNA polymerase, Invitrogen) amplified using
the primers pCJK72_PstI_lacZ_F and pCJK72_KpnI_lacZ_R
(primer sequences are listed in Table S3) and cloned into
pTEX5500ts [48] between PstI and KpnI sites to create pZXL1.
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cassette, the lacZ gene and a gram-positive thermosensitive origin
of replication (repAts, functional at 30uC, but not at 37uC) from
pZXL1 was PCR amplified using the pZXL1_EcoRI _cm_ori_F
and pZXL1_EcoRI _cm_ori_R. Meanwhile, another fragment
containing a nisin inducible mariner transposase C9 and the nisRK
genes (encoding a two-component system required for the
transcriptional activation of the transposase gene in the presence
of nisin), and the ColE1 origin of replication was PCR amplified
from pCJK55 [47] using the primers pCJK55_EcoRI_tps_F and
pCJK55_EcoRI_tps_R. These two fragments were digested with
EcoRI and then ligated together to generate pZXL2. To construct
a mariner transposon [49], the 59 and 39 ITRs of Himar1-mariner
were amplified from pMMOrf [50] using the primer pMMOrf_-
SacII_ITR that resulted in two SacII recognition sites at both ends
of the amplified DNA. The amplified fragment was cloned into
pGEM-T Easy (Promega) forming pGEM-ITR. A gentamicin-
resistance cassette was PCR amplified from pAT392 [51] using
primers pAT392_EheI_T7_genta_F and pAT392_EheI_T7_gen-
ta_R, resulting in a gentamicin-resistance cassette with outward-
facing T7 promoters on both ends of the cassette, which allows for
the generation of RNA products corresponding to the regions
flanking the site of transposon integration in genomic DNA. This
fragment was digested with EheI and cloned into a SmaI site
present between the 59 and 39 ITRs in pGEM-ITR, thereby
forming the transposon cassette. This transposon cassette was then
cut out with SacII and subcloned into the SacII site of pZXL2
producing pZXL3. This vector was electroporated to E. faecium
E1162 but pZXL3 was found to be able to replicate at 37uCi nE.
faecium E1162 and blue/white screening using lacZ proved to be
ineffective (data not shown). We therefore replaced the repAts and
lacZ gene of pZXL3 by the repAts from pAW068 [52]. To this aim,
a fragment of pZXL3 containing the nisin inducible mariner
transposase and the transposon cassette was PCR amplified by
primers pZXL3_BfrI_tn_F and pZXL3_BfrI_tn_R. Another
fragment carrying the repAts and Chl
r cassette was amplified from
pAW068 by PCR using primers pAW068_BfrI_cm_ori_F and
pAW068_BfrI_cm_ori_R. After digestion with BfrI these two
PCR products was ligated together, resulting in the generation of
pZXL5. All restriction enzymes were obtained from New England
Biolabs.
Transposon mutant library construction and evaluation
Electrotransformation of the different E. faecium strains (Table
S1) with the plasmid pZXL5 was performed according to
previously described methodologies [26,34] with optimizations in
preparing electrocompetent cells and the cell-plasmid mixture. To
obtain the electrocompetent cells, overnight cell culture from BHI
was diluted 1000 fold in 25 ml BHI supplemented with 1% of
glycine and 200 mM sucrose and again grown overnight at 37uC.
Cells were then resuspended in same volume of pre-warmed BHI
supplemented with 1% glycine and 200 mM sucrose and
incubated at 37uC for 1 hour. Cells were washed three times
with ice-cold wash buffer (500 mM of sucrose and 10% glycerol),
and resuspended with 1.25 ml ice-cold wash buffer. A 100 ml
aliquot of the cell suspension was mixed with 0.1–1 mg of plasmid
and transferred into an ice-cooled electroporation cuvette (2-mm
gap) and kept on ice for 20 minutes before electroporation.
Gentamicin-resistant transformants were grown overnight in BHI
broth supplemented with 300 mgm l
21 gentamicin and
10 mgm l
21 chloramphenicol at the permissive temperature of
28uC, after which 100 ml (approximately 10
8 viable cells) of this
overnight culture were inoculated in 200 ml of pre-warmed BHI
broth supplemented with gentamicin and 25 ng ml
21 nisin and
grown overnight at the non-permissive temperature of 37uC with
shaking at 150 rpm. Subsequently, 100 ml of this culture was
transferred to 200 ml of fresh pre-warmed BHI broth and
similarly grown overnight without nisin. Cultures were then stored
at 280uC in BHI broth containing 50% (v/v) glycerol in 1 ml
aliquots as mutant library stocks.
To evaluate the randomness and coverage of transposition, we
performed Southern blot analysis, identified the sites of transposon
insertion and used PCR footprinting. Southern blot analysis was
performed as described previously [34]. Genomic DNA of 17
arbitrarily picked gentamicin-resistant colonies from the library
was isolated using the Wizard Genomic DNA Purification kit
(Promega), digested with HaeIII and BamHI. The probe
consisting of a 414 bp fragment within the gentamicin-resistance
gene was amplified from pZXL5 by PCR, using the primer pair
genta_probe_F/R. To map the sites of transposon insertion,
genomic DNA of 17 mutants from the library was digested with
HaeIII and then self-ligated, forming circular DNA. Loci in which
the transposon had inserted were amplified using the transposon-
specific primer pair IPCR_HaeIII_R/F with AccuPrime DNA
polymerases (Invitrogen) with the following conditions: 94uC for
1 min; 32 cycles of 94uC for 18 sec, 53uC for 30 sec, 68uC for
10 min; and 68uC for 7 min. Sequencing of the PCR product was
performed using the primer IPCR_HaeIII_R and/or IPCR_-
HaeIII_F. PCR footprinting was conducted on genomic DNA of
mutant library as described elsewhere [53] with a transposon-
specific primer, ftp_tn, and gene-specific primers, ftp_ddl, ftp_nox
or ftp_esp, respectively.
Simultaneously mapping of transposon insertion sites by
M-TraM
Transposon insertion mapping was based on the previously
published method of Genomic Array Footprinting (GAF) [54].
Because we observed that T7 polymerase will transcribe E. faecium
genomic DNA aspecifically (data not shown), it was required to
modify GAF to specifically enrich for the junction sites of the
transposon and the flanking E. faecium DNA. Genomic DNA from
mutant libraries was isolated using the Wizard Genomic DNA
Purification kit (Promega), digested with AluI (New England
Biolabs) and then purified on a Qiagen QIAquick PCR
Purification column (Qiagen). 200 ng of the digested DNA was
self-ligated by the Quick Ligation Kit (New England Biolabs) in a
reaction volume of 20 ml. This ligation reaction was directly used
as template for PCR amplification of the transposon–chromosome
junctions with primer pair IPCR_AluI_F and IPCR_AluI_R in a
reaction volume of 200 ml, using AccuPrime Taq DNA polymer-
ases High Fidelity (Invitrogen) with the following conditions: 94uC
for 1 min; 26 cycles of 94uC for 18 sec, 56.5uC for 30 sec, 68uC
for 50 sec; and 68uC for 7 min. PCR products were purified using
Qiagen QIAquick PCR Purification Kit. After purification, 200–
500 ng DNA was redigested by AluI and used for in vitro
transcription (IVT) in a volume of 20 ml using the T7 MEGA-
shortscript kit (Ambion) at 37uC for 6 hours. The RNA was first
treated with DNase (Ambion) and then purified with the
MEGAclear Kit (Ambion). 5–10 mg of the purified RNA was
used for generating labeled cDNA using the FairPlay III
Microarray Labeling Kit (Agilent Technologies) as described in
the manufacturer’s protocol. Samples of both conditions (grown in
BHI and BHI with 20 mgm l
21 ampicillin) were labeled with Cy3
or Cy5. Dyes were swapped between samples to minimize the
effect of dye bias. Microarray hybridizations were carried out
using the Gene Expression Hybridization Kit (Agilent) following
the manufacturer’s instructions, using 60 ng of labeled cDNA. The
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replicates.
The microarrays used in this study were custom-made E. faecium
E1162 microarrays using Agilent’s 8615 K platform. Probes were
designed by Agilent’s eArray server. As probes 60-mer oligonu-
cleotides were designed on coding sequences (CDS) only. A total of
2650 CDS are covered by 2 probes (98.4% of the total number of
CDS in the E. faecium E1162 genome sequence; NCBI accession
number NZ_ABQJ00000000), which were spotted in duplicate. A
total of 11 CDS are covered by a single probe (0.4% of the total
number of CDS) and these probes were spotted in quadruplicate.
For 33 CDS no probes could be designed.
Microarray data were extracted and normalized using Agilent
Feature Extraction Software Version 10.7.1.1 (FE 10.7.1).
Statistical differences in hybridization signals between the condi-
tions were analyzed using Cyber-T [55] (http://cybert.
microarray.ics.uci.edu/). Probes exhibiting Bayesian P-val-
ue,0.001 were deemed statistically significant. A gene with two
identical probes or all four probes meeting this criterion were
classified as significantly selected during exposure to ampicillin.
Screening for genes involved in ampicillin resistance
To carry out identification of genes required for ampicillin
resistance, aliquots containing approximately 10
7 CFU from the
mutant pool stored at 280uC were diluted 1 to 1000 in 20 ml of
BHI broth or BHI broth with 20 mgm l
21 ampicillin. Cells were
grown at 37uC for 8 hours, after which 1 ml of the bacteria
cultures were spun down and used for the extraction of genomic
DNA, which was then further processed as described above. The
same protocol (except that the cells were grown for 20 hours
instead of 8 hours) was used to determine the reproducibility of the
M-TraM screening in which two independent mutant libraries
cultures were mapped using the approach described above.
Construction of targeted, markerless deletion mutants
and in trans complementation
For this study, we developed a new method to construct
markerless mutants in E. faecium based on the Cre-lox recombina-
tion system [39]. The 59 and 39 flanking regions (approximately
500 bp each) of the target genes were PCR amplified with the
primers in Table S3. The two flanking regions were then fused
together by fusion PCR (generating an EcoRI site between both
fragments) and cloned into pWS3. Then a gentamicin-resistant
cassette was PCR amplified from pAT392 using primers
pAT392_EcoRI_lox66_genta_F and pAT392_EcoRI_lox71_gen-
ta_R, resulting in a gentamicin-resistant cassette flanked by lox66
and lox71, which allows for the deletion of the gentamicin-resistant
cassette in the presence of Cre recombinase. This fragment was
digested with EcoRI and cloned into the EcoRI site that was
generated between the 59 and 39 flanking regions in the pWS3
construct and then electrotransformed into E. faecium as previously
described [26,48]. A transformant containing the plasmid was
grown overnight in BHI broth at 30uC supplemented with
gentamicin. The cell culture was then diluted 10,000-fold in
prewarmed BHI broth and grown at 37uC overnight without
antibiotics. The cells were then plated on BHI agar plates with
gentamicin and incubated at 37uC. Colonies were then restreaked
on BHI agar plates with spectinomycin and BHI agar plates with
gentamicin, respectively. The gentamicin-resistant but spectino-
mycin-susceptible colonies were supposed to be marked deletion
mutants and checked by PCR (Table S3). To remove the marker
and obtain the markerless mutants a Cre cassette was cut from
pRAB1 [56] by digestion with PstI and SacI, blunted by Quick
Ligation Kit (New England Biolabs) and cloned into the EcoRV site
of pWS3 producing pWS3-Cre, which was subsequently electro-
transformed into the marked mutants. Spectinomycin-resistant
transformants containing pWS3-Cre were then grown overnight in
BHI broth at 30uC supplemented with spectinomycin and then
diluted 10000 fold in pre-warmed BHI broth and grown at 37uC
overnight without antibiotics. These cultures were plated on BHI
agar plates and incubated at 37uC for 18–24 h. Single colonies
were then restreaked on BHI agar with spectinomycin, BHI agar
with gentamicin and BHI agar without antibiotics. The colonies
that were susceptible to both gentamicin and spectinomycin
resulted from a recombination event catalyzed by Cre and
subsequent loss of the thermosensitive plasmid, resulting in a
markerless deletion mutant of the gene of interest. This was
verified by PCR and sequencing.
Insertional mutagenesis was performed as previously described
[34]. Internal DNA fragments of target genes were PCR amplified
using primers listed in Table S3, cloned to a Gram-positive
thermosensitive plasmid and electrotransformed into E. faecium as
previously described [26,48]. After electrotransformation, the cells
were recovered for 2 hours at 30uC, after which the cells were
plated on BHI plates supplemented with 300 mgm l
21 spectino-
mycin at 30uC to select for transformants. Spectinomycin-resistant
colonies were picked and grown overnight in 200 ml of BHI broth
at an elevated temperature (37uC) to cure the plasmid. The cells
were then plated on BHI agar plates with spectinomycin at 37uC.
Single-cross-over integrations into the target genes were verified by
PCR with a pWS3-specific primer, check_pWS3, and a gene-
specific primer (Table S3).
Plasmids for the in trans complementation of the ddcP, ldtfm, lytG
and pbp5 mutants were produced by PCR amplification of the
genes using the primers listed in Table S3. PCR products were
ligated into the downstream region of PnisA promoter of
pMSP3535 [57]. The resulting plasmids were introduced into
the appropriate host strains by electroporation as described above.
Determination of growth curves and MIC
A BioScreen C instrument (Oy Growth Curves AB, Helsinki,
Finland) was used to monitor effects of ampicillin on bacterial
growth. Wild-type E. faecium, mutants and in trans complemented
strains were grown overnight in BHI and BHI containing
appropriate antibiotics. Cells were inoculated at an initial OD660
of 0.0025 into 300 ml BHI and BHI with ampicillin 20 mgm l
21
and 1 mgm l
21.The cultures were incubated in the Bioscreen C
system at 37uC with continuous shaking, and absorbance of
600 nm (A600) was recorded every 15 min for 9 hours. Each
experiment was performed in triplicate.
MIC of ampicillin of the wild-type and mutants were
determined in triplicate by broth microdilution in cation-adjusted
Muller-Hinton broth as previously described [58].
Transcriptome profiling
E. faecium E1162 was incubated in BHI broth and BHI broth
supplemented with 20 mgm l
21 ampicillin for 18 hours. Cultures
were then diluted to OD660 0.025 in 20 ml of prewarmed BHI
brothand BHIbrothcontaining20 mgm l
21 ampicillinrespectively,
and grown until OD6600.3. Cells were centrifuged for12 seconds at
169000 g at room temperature, and pellets were flash frozen in
liquid N2 prior to RNA extraction. RNA was isolated using TRI
Reagent (Ambion) according to the manufacturer’s protocol. RNA
quantity and quality was determined by spectrophotometry
(Nanodrop 1000, Thermo Scientific, Wilmington DE, USA) and
by Bioanalyzer 2100 analysis (Agilent). Labeling of 5 mg of total
RNA, hybridization and data analysis were performed as described
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P,0.001 in Cyber-T [55] were deemed differentially expressed.
Assay for lysozyme sensitivity
To compare the lysozyme sensitivity of the parental strain
E1162, the mutant strains and in trans complemented strains,
overnight cell cultures were diluted 100 fold in fresh BHI and
grown to OD660 0.5. Two ml of the cell cultures were harvested by
centrifugation. The pellets were resuspended in 1 ml phosphate
buffered saline (PBS; NaCl 137 mM; 2.7 mM KCl; 10 mM
Na2HPO4; 2 mM KH2PO4; pH 7.4) as negative control and in
1 ml PBS containing 0.5 mg ml
21 lysozyme. After a 30-minute
incubation at 37uC, cells were washed with PBS and resuspended
in 1 ml of PBS. Survival of the strains was determined following
serial dilution and plating on BHI agar plates. The experiment was
performed in triplicate and statistical analysis of the data was
performed using a two-tailed Student’s t-test.
Determination of D,D-carboxypeptidase activity in
enterococcal extracts
The enzymatic activities in the enterococcal extracts of wild-
type, DddcP and DddcP+ddcP were assayed as described previously
with slight modifications [59,60]. In short, strains were grown until
an OD600 of 0.7. Bacteria were then harvested by centrifugation
and lysed by treatment with lysozyme at 37uC for 1 hour followed
by sonication. The membrane fraction was then pelleted by
ultracentrifugation (100,000 g, 45 min). The supernatant (cyto-
plasmic fractions) was collected and the pellet (membrane
fractions) was resuspended in 0.1 M phosphate buffer (pH 7.0)
and both fractions were assayed for D,D-carboxypeptidase activity
[59,60]. The amounts of D-Ala released from the pentapeptide
(Ala-D-c-Glu-Lys-D-Ala-D-Ala, Sigma-Aldrich) by D,D-carboxy-
peptidases were determined by using D-amino acid oxidase and
horseradish peroxidase in a colorimetric assay.
Microarray data accession numbers
The microarray data generated in this study have been
deposited in the ArrayExpress database (http://www.ebi.ac.uk/
arrayexpress) under accession numbers E-MEXP-3501 for the M-
TraM screening for ampicillin resistance determinants, E-MEXP-
3502 for the assay of the reproducibility of the M-TraM procedure
and E-MEXP-3564 for the transcriptome analysis data.
Supporting Information
Figure S1 Map of pZXL5. This plasmid contains a Gram-
positive thermo-sensitive pWVO1 replicon and the chloramphen-
icol acetyltransferase (cat) gene from pAW068, a nisin inducible
mariner transposase (including nisA promoter, the transposase, nisK
and nisR) and a ColE1 replicon from pCJK55, and a mariner
transposon carrying the gentamicin resistance gene acc(69)-aph(20)
with two outward-facing T7 promoters. Arrows indicate the
direction of transcription. The T7 promoters (PT7) and unique or
relevant restriction sites are shown.
(PDF)
Figure S2 Evaluation of the transposon mutant library in E.
faecium E1162 and electroporation of pZXL5 to four other clinical E.
faecium isolates and subsequent generation of transposon mutant
libraries in strains E745 and E1391. (A) Southern blot analysis of 17
randomly selected E. faecium transposon insertion mutants (lane 1 to
17) from the mutant library. Genomic DNA was digested with
HaeIII and BamHI, and hybridized to an ECL-labeled probe
specific for the transposon. (B) Inverse PCR and sequencing analysis
of 17 randomly selected E. faecium transposon insertion mutants (lane
2 to 18). Genomic DNA was digested with HaeIII, self-ligated and
the transposon-chromosome junction was PCR amplified using
transposon-specificprimers. The PCR products were sequenced and
matched to the E1162 genome sequence. The transposon insertion
loci of the mutants are indicated. (C) Multiplex PCR verification of
the electroporationofpZXL5 into fourclinical E. faeciumstrains.The
expected sizes of the PCR products of ddl (housekeeping gene in the
E. faecium genome) and the gentamicin resistance cassette on the
mariner transposon (in pZXL5) are indicated. The primers used for
the multiplex PCR are listed in Table S3: ftp_ddl and ddl_1 were
used for ddl, genta_in_F and genta_in_R were used for pZXL5. (D)
Inverse PCR and sequencing analysis of randomly selected
transposon insertion mutants from the libraries generated with
E745 and E1391. Five mutants were selected from each library.
Inverse PCR was performed as described in (B).
(TIF)
Figure S3 Predicted protein domain architecture and cellular
localization of Ddcp, Ldtfm, Pgt, and LytG. (A) Protein domain
visualizations and the annotations of protein domains were made
using SMART (Simple Modular Architecture Research Tool) at
http://smart.embl.de/. Blue horizontal bars indicate transmem-
brane regions. Pink stretches indicate regions of low complexity.
Pfam domain Peptidase_S11 in DdcP is predicted to function as a
serine peptidase with D-Ala-D-Ala carboxypeptidases activity. The
PBP5_C domain in DdcP is homologous to the C-terminal
domain of E. coli low-molecular weight penicillin-binding protein
Pbp5, which has no known catalytic function. It could be involved
in mediating interactions with other cell wall-synthesizing
enzymes, thereby allowing the protein to be recruited to areas of
active cell wall synthesis. Alternatively, it could function as a linker
domain that positions the active site in the catalytic domain closer
to the peptidoglycan layer. The two Pfam PG_binding_4 domains
in Ldtfm are predicted to act as a L,D-transpeptidase domain
which can cross-link two peptidoglycan side-chains. The Pfam
YkuD domain in Ldtfm is frequently encountered in proteins with
peptidoglycan-binding domains, but its function is unknown. The
Pfam Glycos_transf_2 domain that is present in Pgt is also found in
a diverse family of glycosyl transferases that transfer a sugar moiety
from an activated nucleotide substrate to a range of substrates
including teichoic acids. The Lyz2 domain that was identified in
LytG is present in eubacterial enzymes that are distantly related to
eukaryotic lysozymes. (B) Cellular localization of the proteins was
predicted by Phobius (http://phobius.sbc.su.se/) and PSORTb
(http://www.psort.org/psortb/; CM: cytoplasmic membrane; C:
cytoplasm; E: extracellular)
(PDF)
Figure S4 Schematic diagram of the Cre-lox recombination
system for the construction of markerless mutant in E. faecium.A
detailed description of the procedure is provided in the Materials
and Methods section. Step 1: The gene replacement construct
carrying in vitro-altered sequences (UpFlankingRegion-lox66-Gmr-
lox71-DownFlankingRegion) is introduced into E1162 by electro-
poration, and transformants are incubated at permissive temper-
ature (30uC) for double crossover events. Step 2: The cells are
passaged at a non-permissive temperature (37uC) for plasmid
replication. Double-crossover integrants, are screened using agar
plates supplemented with appropriate antibiotics. Step 3: Subse-
quently, the thermosensitive plasmid pWS3-Cre is electrotrans-
formed into the marked mutants, and the lox66-Gmr-lox71 cassette
is removed from the chromosome by the Cre-mediated excision
during overnight culture of the transformants at 30uC. Step 4:
Subsequent overnight culturing of the cells at 37uC leads to the
Ampicillin Resistance in E. faecium
PLoS Genetics | www.plosgenetics.org 11 June 2012 | Volume 8 | Issue 6 | e1002804loss of pWS3-Cre, resulting in a markerless double crossover
mutant in which the gene is replaced by a lox72 site. (Gm
r:
gentamicin resistant; Gm
s: gentamicin susceptible; Spc
r: spectino-
mycin resistant; Spc
s: spectinomycin susceptible; Ts: thermosensi-
tive replicon).
(TIF)
Figure S5 Growth curves of targeted mutants and wild-type E.
faecium E1162 in BHI medium without added antibiotics.
Overnight cultures of mutants and wild-type strain were
inoculated at an initial cell density of OD660 0.0025 in BHI and
grown at 37uC with shaking in the Bioscreen C instrument.
Growth curves represent mean data from three independent
experiments.
(PDF)
Table S1 Strains and plasmids used in this study.
(DOC)
Table S2 Expression ratios of E. faecium E1162 genes that exhibit
significant differences in expression during mid-exponential
growth in BHI and BHI with 20 mgm l
21 ampicillin.
(DOCX)
Table S3 Primers used in this study.
(DOC)
Acknowledgments
We thank the following researchers for kindly providing us with plasmids:
David Lampe for pMMorf, Marta Perego for pAW068, Ralph Bertram for
pRAB1, and Chris J. Kristich for pCJK55 and pCJK72.
Author Contributions
Conceived and designed the experiments: XZ WvS. Performed the
experiments: XZ DB AK FLP. Analyzed the data: XZ WvS. Wrote the
paper: XZ RJLW MJMB WvS.
References
1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, et al. (2008) NHSN
annual update: antimicrobial-resistant pathogens associated with healthcare-
associated infections: annual summary of data reported to the National
Healthcare Safety Network at the Centers for Disease Control and Prevention,
2006–2007. Infect Control Hosp Epidemiol 29: 996–1011.
2. Willems RJ, van Schaik W (2009) Transition of Enterococcus faecium from
commensal organism to nosocomial pathogen. Future Microbiol 4: 1125–1135.
3. Ammerlaan HS, Troelstra A, Kruitwagen CL, Kluytmans JA, Bonten MJ (2009)
Quantifying changes in incidences of nosocomial bacteraemia caused by
antibiotic-susceptible and antibiotic-resistant pathogens. J Antimicrob Che-
mother 63: 1064–1070.
4. Top J, Willems R, Blok H, de Regt M, Jalink K, et al. (2007) Ecological
replacement of Enterococcus faecalis by multiresistant clonal complex 17 Enterococcus
faecium. Clin Microbiol Infect 13: 316–319.
5. Leavis HL, Bonten MJ, Willems RJ (2006) Identification of high-risk
enterococcal clonal complexes: global dispersion and antibiotic resistance. Curr
Opin Microbiol 9: 454–460.
6. van Schaik W, Willems RJ (2010) Genome-based insights into the evolution of
enterococci. Clin Microbiol Infect 16: 527–532.
7. Arias CA, Contreras GA, Murray BE (2010) Management of multidrug-resistant
enterococcal infections. Clin Microbiol Infect 16: 555–562.
8. Murdoch DR, Mirrett S, Harrell LJ, Monahan JS, Reller LB (2002) Sequential
emergence of antibiotic resistance in enterococcal bloodstream isolates over 25
years. Antimicrob Agents Chemother 46: 3676–3678.
9. Grayson ML, Eliopoulos GM, Wennersten CB, Ruoff KL, De Girolami PC, et
al. (1991) Increasing resistance to beta-lactam antibiotics among clinical isolates
of Enterococcus faecium: a 22-year review at one institution. Antimicrob Agents
Chemother 35: 2180–2184.
10. Murray BE (2000) Vancomycin-resistant enterococcal infections. N Engl J Med
342: 710–721.
11. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, et al. (2008)
Emergence and spread of vancomycin resistance among enterococci in Europe.
Euro Surveill 13: pii: 19046.
12. Montero CI, Stock F, Murray PR (2008) Mechanisms of resistance to
daptomycin in Enterococcus faecium. Antimicrob Agents Chemother 52: 1167–
1170.
13. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C (2008)
Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant
Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob
Agents Chemother 52: 2256–2259.
14. Arias CA, Panesso D, McGrath DM, Qin X, Mojica MF, et al. (2011) Genetic
basis for in vivo daptomycin resistance in enterococci. N Engl J Med 365: 892–
900.
15. Murray BE (1990) The life and times of the Enterococcus. Clin Microbiol Rev 3:
46–65.
16. Fontana R, Grossato A, Rossi L, Cheng YR, Satta G (1985) Transition from
resistance to hypersusceptibility to beta-lactam antibiotics associated with loss of
a low-affinity penicillin-binding protein in a Streptococcus faecium mutant highly
resistant to penicillin. Antimicrob Agents Chemother 28: 678–683.
17. Williamson R, le Bouguenec C, Gutmann L, Horaud T (1985) One or two low
affinity penicillin-binding proteins may be responsible for the range ofsusceptibility
of Enterococcus faecium to benzylpenicillin. J Gen Microbiol 131: 1933–1940.
18. Fontana R, Aldegheri M, Ligozzi M, Lopez H, Sucari A, et al. (1994)
Overproduction of a low-affinity penicillin-binding protein and high-level
ampicillin resistance in Enterococcus faecium. Antimicrob Agents Chemother 38:
1980–1983.
19. Galloway-Pena JR, Rice LB, Murray BE (2011) Analysis of PBP5 of Early U.S.
Isolates of Enterococcus faecium: Sequence Variation Alone Does Not Explain
Increasing Ampicillin Resistance over Time. Antimicrob Agents Chemother 55:
3272–3277.
20. Rice LB, Bellais S, Carias LL, Hutton-Thomas R, Bonomo RA, et al. (2004)
Impact of specific pbp5 mutations on expression of beta-lactam resistance in
Enterococcus faecium. Antimicrob Agents Chemother 48: 3028–3032.
21. Mainardi JL, Legrand R, Arthur M, Schoot B, van Heijenoort J, et al. (2000)
Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptida-
tion in Enterococcus faecium. J Biol Chem 275: 16490–16496.
22. Mainardi JL, Morel V, Fourgeaud M, Cremniter J, Blanot D, et al. (2002)
Balance between two transpeptidation mechanisms determines the expression of
beta-lactam resistance in Enterococcus faecium. J Biol Chem 277: 35801–35807.
23. Sacco E, Hugonnet JE, Josseaume N, Cremniter J, Dubost L, et al. (2010)
Activation of the L,D-transpeptidation peptidoglycan cross-linking pathway by a
metallo-D,D-carboxypeptidase in Enterococcus faecium. Mol Microbiol 75: 874–
885.
24. van Schaik W, Top J, Riley DR, Boekhorst J, Vrijenhoek JE, et al. (2010)
Pyrosequencing-based comparative genome analysis of the nosocomial pathogen
Enterococcus faecium and identification of a large transferable pathogenicity island.
BMC Genomics 11: 239.
25. Walsh CT (1989) Enzymes in the D-alanine branch of bacterial cell wall
peptidoglycan assembly. J Biol Chem 264: 2393–2396.
26. Heikens E, Bonten MJ, Willems RJ (2007) Enterococcal surface protein Esp is
important for biofilm formation of Enterococcus faecium E1162. J Bacteriol 189:
8233–8240.
27. Heikens E, Singh KV, Jacques-Palaz KD, van Luit-Asbroek M, Oostdijk EA, et
al. (2011) Contribution of the enterococcal surface protein Esp to pathogenesis of
Enterococcus faecium endocarditis. Microbes Infect 13: 1185–1190.
28. Leendertse M, Heikens E, Wijnands LM, van Luit-Asbroek M, Teske GJ, et al.
(2009) Enterococcal surface protein transiently aggravates Enterococcus faecium-
induced urinary tract infection in mice. J Infect Dis 200: 1162–1165.
29. Lam MM, Seemann T, Bulach DM, Gladman SL, Chen H, et al. (2012)
Comparative Analysis of the First Complete Enterococcus faecium Genome.
J Bacteriol 194: 2334–2341.
30. Sauvage E, Kerff F, Terrak M, Ayala JA, Charlier P (2008) The penicillin-
binding proteins: structure and role in peptidoglycan biosynthesis. FEMS
Microbiol Rev 32: 234–258.
31. Lei XH, Fiedler F, Lan Z, Kathariou S (2001) A novel serotype-specific gene
cassette (gltA-gltB) is required for expression of teichoic acid-associated surface
antigens in Listeria monocytogenes of serotype 4b. J Bacteriol 183: 1133–1139.
32. Horsburgh GJ, Atrih A, Williamson MP, Foster SJ (2003) LytG of Bacillus subtilis
is a novel peptidoglycan hydrolase: the major active glucosaminidase.
Biochemistry 42: 257–264.
33. Magnet S, Arbeloa A, Mainardi JL, Hugonnet JE, Fourgeaud M, et al. (2007)
Specificity of L,D-transpeptidases from gram-positive bacteria producing
different peptidoglycan chemotypes. J Biol Chem 282: 13151–13159.
34. Zhang X, Vrijenhoek JE, Bonten MJ, Willems RJ, Van Schaik W (2011) A
genetic element present on megaplasmids allows Enterococcus faecium to use
raffinose as carbon source. Environ Microbiol 13: 518–528.
35. Callewaert L, Michiels CW (2010) Lysozymes in the animal kingdom. J Biosci
35: 127–160.
36. Kang Y, Durfee T, Glasner JD, Qiu Y, Frisch D, et al. (2004) Systematic
mutagenesis of the Escherichia coli genome. J Bacteriol 186: 4921–4930.
37. Christen B, Abeliuk E, Collier JM, Kalogeraki VS, Passarelli B, et al. (2011) The
essential genome of a bacterium. Mol Syst Biol 7: 528.
38. Galloway-Pena JR, Nallapareddy SR, Arias CA, Eliopoulos GM, Murray BE
(2009) Analysis of clonality and antibiotic resistance among early clinical isolates
of Enterococcus faecium in the United States. J Infect Dis 200: 1566–1573.
Ampicillin Resistance in E. faecium
PLoS Genetics | www.plosgenetics.org 12 June 2012 | Volume 8 | Issue 6 | e100280439. Sauer B (1987) Functional expression of the cre-lox site-specific recombination
system in the yeast Saccharomyces cerevisiae. Mol Cell Biol 7: 2087–2096.
40. Ghosh AS, Chowdhury C, Nelson DE (2008) Physiological functions of D-
alanine carboxypeptidases in Escherichia coli. Trends Microbiol 16: 309–317.
41. Sarkar SK, Chowdhury C, Ghosh AS (2010) Deletion of penicillin-binding
protein 5 (PBP5) sensitises Escherichia coli cells to beta-lactam agents.
Int J Antimicrob Agents 35: 244–249.
42. Memmi G, Filipe SR, Pinho MG, Fu Z, Cheung A (2008) Staphylococcus aureus
PBP4 is essential for beta-lactam resistance in community-acquired methicillin-
resistant strains. Antimicrob Agents Chemother 52: 3955–3966.
43. Campbell J, Singh AK, Santa Maria JP, Jr., Kim Y, Brown S, et al. (2011)
Synthetic lethal compound combinations reveal a fundamental connection
between wall teichoic acid and peptidoglycan biosyntheses in Staphylococcus aureus.
ACS Chem Biol 6: 106–116.
44. Leavis HL, Willems RJ, van Wamel WJ, Schuren FH, Caspers MP, et al. (2007)
Insertion sequence-driven diversification creates a globally dispersed emerging
multiresistant subspecies of E. faecium. PLoS Pathog 3: e7. doi:10.1371/
journal.ppat.0030007
45. Bush LM, Calmon J, Cherney CL, Wendeler M, Pitsakis P, et al. (1989) High-
level penicillin resistance among isolates of enterococci. Implications for
treatment of enterococcal infections. Ann Intern Med 110: 515–520.
46. Leenhouts K, Buist G, Bolhuis A, ten Berge A, Kiel J, et al. (1996) A general
system for generating unlabelled gene replacements in bacterial chromosomes.
Mol Gen Genet 253: 217–224.
47. Kristich CJ, Nguyen VT, Le T, Barnes AM, Grindle S, et al. (2008)
Development and use of an efficient system for random mariner transposon
mutagenesis to identify novel genetic determinants of biofilm formation in the
core Enterococcus faecalis genome. Appl Environ Microbiol 74: 3377–3386.
48. Nallapareddy SR, Singh KV, Murray BE (2006) Construction of improved
temperature-sensitive and mobilizable vectors and their use for constructing
mutations in the adhesin-encoding acm gene of poorly transformable clinical
Enterococcus faecium strains. Appl Environ Microbiol 72: 334–345.
49. Akerley BJ, Lampe DJ (2002) Analysis of gene function in bacterial pathogens by
GAMBIT. Methods Enzymol 358: 100–108.
50. Lampe DJ, Akerley BJ, Rubin EJ, Mekalanos JJ, Robertson HM (1999)
Hyperactive transposase mutants of the Himar1 mariner transposon. Proc Natl
Acad Sci U S A 96: 11428–11433.
51. Arthur M, Depardieu F, Snaith HA, Reynolds PE, Courvalin P (1994)
Contribution of VanY D,D-carboxypeptidase to glycopeptide resistance in
Enterococcus faecalis by hydrolysis of peptidoglycan precursors. Antimicrob Agents
Chemother 38: 1899–1903.
52. Wilson AC, Perego M, Hoch JA (2007) New transposon delivery plasmids for
insertional mutagenesis in Bacillus anthracis. J Microbiol Methods 71: 332–335.
53. Chaudhuri RR, Allen AG, Owen PJ, Shalom G, Stone K, et al. (2009)
Comprehensive identification of essential Staphylococcus aureus genes using
Transposon-Mediated Differential Hybridisation (TMDH). BMC Genomics
10: 291.
54. Bijlsma JJ, Burghout P, Kloosterman TG, Bootsma HJ, de Jong A, et al. (2007)
Development of genomic array footprinting for identification of conditionally
essential genes in Streptococcus pneumoniae. Appl Environ Microbiol 73: 1514–
1524.
55. Baldi P, Long AD (2001) A Bayesian framework for the analysis of microarray
expression data: regularized t -test and statistical inferences of gene changes.
Bioinformatics 17: 509–519.
56. Leibig M, Krismer B, Kolb M, Friede A, Gotz F, et al. (2008) Marker removal in
staphylococci via Cre recombinase and different lox sites. Appl Environ
Microbiol 74: 1316–1323.
57. Bryan EM, Bae T, Kleerebezem M, Dunny GM (2000) Improved vectors
for nisin-controlled expression in gram-positive bacteria. Plasmid 44: 183–
190.
58. Andrews JM (2001) Determination of minimum inhibitory concentrations.
J Antimicrob Chemother 48 Suppl 1: 5–16.
59. Lebreton F, Depardieu F, Bourdon N, Fines-Guyon M, Berger P, et al. (2011) D-
Ala-D-Ser VanN-Type Transferable Vancomycin Resistance in Enterococcus
faecium. Antimicrob Agents Chemother 55: 4606–4612.
60. Arthur M, Depardieu F, Reynolds P, Courvalin P (1996) Quantitative analysis of
the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-
resistant enterococci. Mol Microbiol 21: 33–44.
Ampicillin Resistance in E. faecium
PLoS Genetics | www.plosgenetics.org 13 June 2012 | Volume 8 | Issue 6 | e1002804